BP180NC16a与大疱性类天疱疮病情变化的关系

目的探讨大疱性类天疱疮(BP)患者外周血血清IIF滴度、BP180NC16a-ELISA指数与病情变化的相关性。方法监测12例以系统糖皮质激素治疗为主的泛发性BP患者不同时期病情变化及其相应的IIF滴度和BP180NC16a-ELISA指数,并对结果进行分析。结果IIF滴度与病情变化没有平行关系,BP180NC16a-ELISA指数与病情变化较平行。结论BP180NC16a-ELISA指数可作为BP病情的监测和调整治疗方案的重要参考。     

抗BP180NC16A IgG亚型检测方法的建立以及在大疱性类天疱疮中的意义

【摘要】 目的 建立抗BP180NC16A IgG亚型的检测方法,并探讨其在大疱性类天疱疮（BP）中的意义。方法 原核表达GST-NC16A融合蛋白,并采用亲和层析法纯化。优化ELISA关键环节,建立抗BP180NC16A IgG各亚型的ELISA检测方法,并对10例未经治疗的BP、5例妊娠疱疹、1例成人线状IgA大疱性皮病、2例天疱疮患者血清分别进行检测。结果 通过方阵测定法确定GST-NC16A融合蛋白的包被浓度为500 μg/L,包被条件为4 ℃ 12 h,血清稀释倍数为1 ∶ 100,酶标二抗为1 ∶ 2000,孵育条件为37 ℃ 1 h,底物反应条件37 ℃ 20 min。10例大疱性类天疱疮患者10例IgG1阳性,9例IgG2阳性,5例IgG3阳性,9例IgG4阳性。2例寻常型天疱疮、1例成人线状IgA大疱性皮病均阴性。5例妊娠疱疹所有亚型均阳性,以IgG1和IgG3亚型为主。结论 抗BP180NC16A ELISA检测法特异性强、重复性好,是检测BP和妊娠疱疹患者抗BP180NC16A抗体亚型的半定量方法。     

以BP180NC16a融合蛋白检测大疱性类天疱疮抗体

为了研究大疱性类天疱疮（ＢＰ）的ＢＰ１８０抗原上的抗体结合表位，了解ＢＰ血清中抗体与ＢＰ１８０ＮＣ１６ａ融合蛋白反应的关系，进一步探讨分子生物学技术运用于表皮下大疱性皮肤病的病因分析和临床诊断，用基因工程技术，制备原核细胞内表达的完整性ＢＰ１８０ＮＣ１６ａ区段融合蛋白，以此为抗原用免疫印迹法检测了６４例ＢＰ血清、２例瘢痕性类天疱疮（ＣＰ）血清。结果在６４例ＢＰ血清中４８例阳性（７５．０％），用人表     

BP180NC16a-ELISA对大疱性类天疱疮血清学诊断的评价

目的 评价BP180NC16a-ELISA对大疱性类天疱疮血清学诊断的效能.方法 BP患者42例,对照组42例(其中正常人对照24例,天疱疮18例),在患者用药前采血,比较BP180NC16a-ELISA和盐裂试验免疫荧光(IIF)检测的结果.结果 用BP180NC16a-ELISA检测时,BP患者中有1例呈阴性反应,其敏感性为97.62%;正常人对照组中有1例呈阳性反应,其特异性为97.62%,且BP180NC16a-ELISA法的A值与IIF滴度之间无相关性.结论 BP180NC16a-ELISA在疾病初始阶段是检测血清中抗BP180抗体的有效方法.     

重组原核表达载体pGEX-4T-1-eIF5A的构建及表达

目的构建人eIF5A基因的融合表达载体并在大肠杆菌中诱导表达pGEX-4T-1-eIF5A融合蛋白。方法以pCMV6-XL4-eIF5A作为模板,经PCR技术扩增目的片段,将获得的目的片段重组到原核表达载体pGEX-4T-1上,经酶切鉴定、DNA测序检测插入序列的正确性。将测序正确的重组表达质粒pGEX-4T-1-eIF5A转化到E.coliBL21内,经IPTG诱导后,GSTpull-down后SDS-PAGE电泳分析以及Western blot检测人eIF5A的表达。结果成功构建重组表达质粒pGEX-4T-1-eIF5A,经DNA测序证实插入序列与设计完全一致,GSTpull-down后电泳分析以及Westernblot结果说明大肠杆菌BL21诱导后表达出人eIF5A的glutathioneS-transferase(GST)融合蛋白。功能研究初步证明重组eIF5A在细胞增殖过程中发挥重要作用。结论构建成功的重组原核表达载体能在E.coliBL21内表达eIF5A的GST融合蛋白,为进一步研究人eIF5A蛋白的结构和生理功能如促进创伤修复提供帮助。     

人源性抗大疱性类天疱疮抗原BP180-NC16A单链抗体的构建及表达

目的用基因工程技术制备人源性抗大疱性类天疱疮抗原BP180单链抗体(scFv),并对其抗原结合特异性等进行鉴定。方法利用基因重组技术对从噬菌体抗体库中克隆的人源性抗大疱性类天疱疮抗原BP180-NC16A抗体Fab片段进行改造获得scFv,进行DNA测序,同时用ELISA法鉴定其抗原结合活性和特异性,免疫荧光技术检测scFv与人皮肤组织BP180抗原的结合情况。结果成功构建了抗BP180-NC16A scFv,并获得可溶性表达,DNA测序结果表明,单链抗体的Vλ和VH基因序列完全正确,ELISA法证实可溶性表达的scFv抗体具有良好的抗原结合活性和特异性。免疫荧光检测该抗体在人皮肤表皮、真皮交界处基底膜带呈现线状结合条带。结论成功构建并表达了人源性抗大疱性类天疱疮抗原BP180-NC16A的单链抗体,为进一步研究该抗体的生物学作用奠定了基础。     

单纯疱疹病毒Ⅱ型潜伏相关转录体基因ORF真核表达载体的构建及表达

目的 构建单纯疱疹病毒Ⅱ型潜伏相关转录体基因ORF片段真核表达载体,并在Vero细胞中进行表达. 方法用PCR方法从已成功构建的pVAX-LAT重组质粒中扩增潜伏相关转录体基因ORF片段,克隆到pcDNA 6/myc-his B质粒中,构建pcDNA-ORF重组质粒,双酶切及测序鉴定其正确性.以脂质体法瞬时转染Vero细胞,并用RT-PCR和Western blot检测其表达. 结果双酶切及测序表明ORF片段大小及序列均正确,RT-PCR及Western blot显示重组质粒在Vero细胞中得到了表达. 结论成功构建了pcDNA-ORF重组质粒,并可在Vero细胞内有效表达.     

皮肤鳞状细胞癌中p16蛋白、细胞周期蛋白D1的表达及其意义

皮肤鳞状细胞癌(以下简称鳞癌)的发生发展是一个多因素、多阶段逐渐演进的过程。其中包括多种癌基因和抑癌基因的异常表达。p16蛋白、细胞周期蛋白(cyclin)D1表达异常在多种肿瘤的发生过程中起重要作用。为了检测p16蛋白、细胞周期蛋白D1在皮肤鳞癌组织中的表达情况及其相互关系．笔者应用免疫组化方法对40例原发性皮肤鳞癌组织和10名正常人皮肤组织进行研究分析，现将结果报告如下。     

大疱性类天疱疮患者噬菌体抗体库的构建及抗BP180-NC16A抗体筛选

目的构建噬菌体抗体库并筛选抗BP180-NC16A抗体。方法以大疱性类天疱疮(BP)患者外周血淋巴细胞为基因来源,扩增多样性的轻链和重链Fd段基因,构建Fab段表面展示的噬菌体抗体库,用BP180分子的NC16A片段为抗原对抗体库进行筛选并对筛选得到的抗体用ELISA,W estern b lot和免疫荧光等方法进行鉴定。结果经过轻、重链基因的重组和转化,获得了库容为5×107的噬菌体抗体库。以BP180-NC16A抗原进行"亲和吸附—洗脱—扩增"淘筛,获得2株特异性抗体。结论利用噬菌体抗体库技术成功制备了抗BP180抗体,为深入研究BP自身抗体、探讨新的治疗策略奠定了基础。     

pcDNA.3.1/myc-His(-)A-HINT1真核表达载体的构建及其在人黑素瘤细胞A375中的表达

目的:构建真核表达载体pcDNA.3.1/myc-His(-)A-HINT1并检测其在人黑素瘤细胞A375中的表达.方法:采用巢式RT-PCR的方法扩增带有Xba I和Kpn I酶切位点的人HINT1编码区基因,经TA克隆技术,将基因测序正确的序列克隆到空白真核表达载体pcDNA.3.1/myc-His(-)A,构建真核表达载体pcDNA.3.1/myc-His(-)A-HINT1.经菌落PCR、双酶切及基因测序鉴定后,用脂质体转染法转染A375细胞,通过G418筛选,获得稳定转染的A375单克隆细胞.用免疫细胞化学法及Western blot(WB)法检测HINT1蛋白在细胞中的表达.结果:pcDNA.3.1/myc-His(-)A-HINT1真核表达载体构建成功,通过脂质体转染,G418筛选,获得稳定转染的A375单克隆细胞,免疫细胞化学及WB检测均显示稳定转染真核表达载体pcDNA.3.1/myc-His(-)A-HINT1的A375单克隆细胞有更高的HINT1蛋白的表达.结论:成功构建了pcDNA.3.1/myc-His(-)A-HINT1真核表达载体,并获得稳定转染且能高表达HINT1的单克隆A375细胞.     

大疱性类天疱疮和妊娠疱疹患者血清抗BP180 NC16A抗体的纯化和鉴定

目的 探讨大疱性类天疱疮（BP）和妊娠疱疹（HG）患者血清抗BPl80 NC16A 抗体的纯化和鉴定方法。方法 原核表达系统pGEX-2TBP180NC16A表达GST/NC16A融合蛋白,将融合蛋白与谷胱甘肽琼脂糖凝聚微珠进行共价偶联。微珠亲和层析法纯化BP和HG患者血清中抗BP180 NC16A抗体,并用ELISA、免疫荧光、及Western印迹进行鉴定。结果 原核表达系统pGEX-2TBP180NC16A表达37 000 GST/NC16A融合蛋白,微珠亲和层析法纯化后得单一抗BP180 NC16A抗体。经ELISA方法定量后确定其含量为2.4 mg/ml;该抗体能与人皮肤基底膜带结合,证明抗体活性;免疫印迹可见单一片段,显示抗体纯度。结论 微珠亲和层析法纯化的BP和HG患者血清中抗BP180 NC16A自身抗体活性高、特异性强。     

BP180NC16a-ELISA检测大疱性类天疱疮多中心随机双盲对照试验

目的 探讨BP180抗体诊断试剂盒检测大疱性类天疱疮（BP）的灵敏度和特异度。方法 多中心随机双盲平行对照临床试验。使用BP180抗体诊断试剂盒（ELISA）检测106例临床已经确诊的活动期BP患者和106例对照人群（含非BP的其他大疱性疾病以及硬皮病、银屑病、SLE、妊娠晚期孕妇、健康献血员等）血清样本,并与间接免疫荧光（IIF）试验进行灵敏度和特异度的对比。结果 106份BP患者血清样本中81份BP180抗体诊断试剂盒为阳性,其灵敏度为76.4%;83份抗表皮抗原抗体检测试剂盒（IIF法）为阳性,其灵敏度为78.3%。106份对照组血清标本中95份BP180抗体诊断试剂盒为阴性,其特异度为89.6%;102份抗表皮抗原抗体检测试剂盒为阴性,其特异度为96.2%。BP180抗体诊断试剂盒（ELISA）与对照试剂盒的灵敏度和特异度相比较,差异无统计学意义（P > 0.05）。结论 BP180抗体诊断试剂盒可作为诊断BP的一种辅助手段。     

Rapid effector function of circulating NC16A-specific T cells in individuals with mucous membrane pemphigoid

BACKGROUND: Mucous membrane pemphigoid (MMP) is a chronic blistering skin disease frequently associated with circulating autoantibodies directed to a number of antigens including the NC16A region of BP180. NC16A domain-specific T cells have been identified in the blood of individuals with bullous pemphigoid (BP), pemphigoid gestationis and linear IgA disease, but there are no data investigating the potential role for such T cells in the pathogenesis of MMP. OBJECTIVES: To test the hypothesis that NC16A-specific T cells exist in the peripheral blood of individuals with MMP. METHODS: We isolated peripheral blood mononuclear cells from 10 patients with MMP, 17 with BP and 10 healthy controls and examined the immunogenicity of overlapping peptides spanning the NC16A domain using interferon (IFN)-gamma enzyme-linked immunospot assay. RESULTS: Significant IFN-gamma production was observed in response to the NC16A peptides in two of the patients with MMP and two of the patients with BP but in none of the normal controls. These data suggest that in a minority of individuals with MMP, NC16A domain-specific T cells circulate at sufficiently high frequency to be detectable directly ex vivo and to show rapid effector function. CONCLUSIONS: Overall, these findings are the first to examine the potential role for antigen-specific autoreactive T cells in the pathogenesis of MMP, and confirm that in some individuals the NC16A domain may be an important target antigen.     

T cells reactive with the NC16A domain of BP180 are present in vulval lichen sclerosus and lichen planus

Background Lichen sclerosus (LS) is a chronic inflammatory skin condition. The recent demonstration of circulating autoantibodies to extracellular matrix protein 1 and to basement membrane zone (BMZ) components, chiefly BP180, suggests that autoimmunity to these components might contribute to pathogenesis. However, there is no binding of autoantibodies in vivo and as LS is characterized by a lymphocytic infiltrate, it seems likely that LS is mediated, in part, by antigen‐specific lymphocytes. Similar mechanisms may apply to vulval lichen planus (LP), an interface dermatitis, with clinical and immunological overlap with LS. Objectives This study aims to test the hypothesis that T cells reactive with the NC16A domain of BP180 are present in the peripheral blood of patients with vulval LS and LP. Methods Isolated peripheral blood mononuclear cells from 14 patients with vulval LS, 5 with vulval LP and 4 healthy controls were grown in vitro. We examined for immunogenicity of overlapping peptides spanning the NC16A domain of BP180 using interferon‐γ enzyme‐linked immunospot assay (ELIspot) on the cultured T‐cell lines. BMZ antibodies were assayed, HLA type determined and clinical parameters noted. Results Significant interferon‐γ production was observed in response to the NC16A peptides in 6 of the 14 vulval LS and 2 of the 5 LP patients, but not in the control subjects. There was an associated autoantibody response to BP180 in 3 LS and 1 LP patient with T‐cell responses. These data suggest that in some vulval LS and LP patients, NC16A domain‐specific T cells circulate at sufficiently high frequency to be detectable in vitro and show rapid effector function. There was no association with HLA type or clinical parameters. Conclusion We have demonstrated that in > 40% of our vulval LS and LP patients, the NC16A domain of BP180 is a target for circulating T cells, and in vulval LS and LP there are associated autoantibodies to BP180.     

Usefulness of Enzyme-linked Immunosorbent Assay Using Recombinant BP180 and BP230 for Serodiagnosis and Monitoring Disease Activity of Bullous Pemphigoid

Background

Bullous pemphigoid (BP) is an autoimmune subepidermal bullous disease associated with autoantibodies against BP180 and BP230. Enzyme-linked immunosorbent assay (ELISA) is a sensitive tool for the detection of immunoglobulin G (IgG) anti-BP180 and anti-BP230 autoantibodies.

Objective

The aim of this study was to evaluate the usefulness of ELISA for diagnosing and monitoring the disease activity of BP.

Methods

We evaluated serum IgG levels of anti-BP180 and anti-BP230 autoantibodies in 47 BP patients, 16 epidermolysis bullosa aquisita patients, and 15 healthy volunteers using ELISA. Through retrospective review of the medical records, the clinical characteristics of BP including disease activity, duration, pruritus severity and peripheral blood eosinophil counts were assessed.

Results

The sensitivity of BP180 ELISA was 97.9%, BP230 ELISA 72.3%, and a combination of the two was 100%. The specificity of BP180 ELISA was 90.3%, BP230 ELISA 100%, and a combination of the two was 90.3%. BP180 ELISA scores showed strong associations with disease activity, pruritus severity, peripheral blood eosinophil counts, and disease duration, whereas BP230 ELISA scores did not.

Conclusion

BP180 and BP230 ELISAs are highly sensitive methods for the diagnosis of BP, and BP180 ELISA, in particular, is a sensitive tool for monitoring the disease activity of BP.     

GST-HPV58 E6融合蛋白的表达与纯化

目的体外克隆并表达HPV58 E6,为研究HPV58 E6的致癌机理及制备预防性疫苗奠定基础。方法利用PCR反应及基因重组技术,从HPV58全基因组中扩增出HPV58 E6基因片段,并将其插入带有GST(谷胱甘肽巯基转移酶)标签的原核表达载体,IPTG诱导表达。结果基因测序分析、酶切电泳证实重组质粒pGEX-4T-3/HPV58 E6序列正确,并可在大肠杆菌中高效表达,进一步经G lutath ione Sepharose 4B获得纯化的GST-HPV58E6融合蛋白。结论成功构建了人pGEX-4T-3/HPV58 E6原核表达载体,表达并纯化了GST-HPV58 E6蛋白,为其致癌作用的研究奠定了基础。